Nektar Therapeutics - Common Stock (NKTR)

One of the company's pipeline drugs is showing significant promise.

Nektar reported Phase 2b results showing rezpegaldesleukin improved eczema severity scores and met primary and key secondary endpoints in patients.

The company's competitive positioning might be stronger now, after disappointing results from a key rival.

Nektar Therapeutics stock is trading higher with no news, possibly due to Sanofi's disappointing results.

Is it too late to get on the bandwagon?

Results of the Resolve-AD trial with rezpegaldesleukin were better than expected.

Here's what needs to happen for these high flyers to continue soaring.

The company said it has sufficient financial resources to fund its operations into early 2027.

These small-cap biotech stocks offer high-reward potential with bullish momentum and key catalysts ahead in urology, autoimmune, and gene editing therapies

U.S. futures slipped on Tuesday after two days of record-setting advances. Futures of major benchmark indices were trading lower.

With major rallies and analyst backing, Nektar, Cidara, and GeneDx are drawing interest; will these biopharma firms maintain their growth trajectories?

Nektar Therapeutics soared 157% after Rezpeg succeeded in a Phase 2b eczema trial. Analysts forecast huge upside—here’s why there could be more gains ahead.

The data showed strong efficacy across multiple endpoints and consistent safety, reinforcing confidence in rezpegaldesleukin’s potential as a differentiated treatment for atopic dermatitis.

Nektar's rezpegaldesleukin met key efficacy targets in a mid-stage eczema study, though analysts flagged safety and differentiation concerns.